<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00031915</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000069239</org_study_id>
    <secondary_id>NCI-02-C-0097</secondary_id>
    <secondary_id>CCUM-2001-034</secondary_id>
    <secondary_id>CPMC-IRB-14060</secondary_id>
    <nct_id>NCT00031915</nct_id>
    <nct_alias>NCT00029094</nct_alias>
  </id_info>
  <brief_title>Imatinib Mesylate in Treating Patients With Advanced Soft Tissue Sarcoma or Bone Sarcoma</brief_title>
  <official_title>Phase II Trial of Gleevec (Formerly Known as STI571) in Patients With Soft Tissue and Bone Sarcomas: A Multi-Disciplinary Trial of the North American Sarcoma Study Group of the Connective Tissue Oncology Society</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Imatinib mesylate may stop the growth of tumor cells by blocking the enzymes
      necessary for cancer cell growth.

      PURPOSE: Phase II trial to study the effectiveness of imatinib mesylate in treating patients
      who have metastatic or unresectable locally advanced soft tissue sarcoma or bone sarcoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Determine the efficacy of imatinib mesylate, as measured by response rate, in patients
           with metastatic or unresectable locally advanced soft tissue or bone sarcoma who have
           failed one or more prior treatment regimens.

        -  Determine the clinical and laboratory toxic effects of this drug in these patients.

      OUTLINE: This is a multicenter study. Patients are stratified according to disease subtype.

      Patients receive oral imatinib mesylate twice daily. Treatment continues for 1 year in the
      absence of disease progression or unacceptable toxicity.

      PROJECTED ACCRUAL: A total of 60-120 patients (6-12 per stratum) will be accrued for this
      study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2002</start_date>
  <completion_date type="Actual">May 2007</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <condition>Childhood Malignant Fibrous Histiocytoma of Bone</condition>
  <condition>Sarcoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>imatinib mesylate</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically or cytologically confirmed metastatic or unresectable locally advanced
             (stage IV or recurrent) soft tissue or bone sarcoma

               -  Eligible subtypes:

                    -  Ewing's family (e.g., primitive neuroectodermal tumor)

                    -  Osteosarcoma

                    -  Synovial sarcoma

                    -  Rhabdomyosarcoma (e.g., alveolar, embryonal, or pleomorphic)

                    -  Liposarcoma (all variants)

                    -  Malignant fibrous histiocytoma

                    -  Peripheral nerve sheath (e.g., malignant peripheral nerve sheath tumor,
                       neurofibrosarcoma, or schwannoma)

                    -  Fibrosarcoma

                    -  Angiosarcoma (all variants)

               -  Failed standard therapy with no available salvage regimens

          -  Unidimensionally measurable target lesions by x-ray, CT scan, MRI, PET, or physical
             examination

               -  Must be outside prior irradiation fields or have documented disease progression
                  at least 6 weeks after completion of prior radiotherapy

        PATIENT CHARACTERISTICS:

        Age:

          -  10 and over

        Performance status:

          -  Not specified

        Life expectancy:

          -  Not specified

        Hematopoietic:

          -  Not specified

        Hepatic:

          -  Bilirubin no greater than 3 times upper limit of normal (ULN)

          -  ALT and AST less than 2.5 times ULN

        Renal:

          -  Creatinine less than 1.5 times ULN

        Other:

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective barrier contraception during and for at least 1
             week after study participation for female patients and for at least 3 months after
             study participation for male patients

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  Not specified

        Chemotherapy:

          -  Not specified

        Endocrine therapy:

          -  No hormonal birth control

        Radiotherapy:

          -  See Disease Characteristics

          -  At least 3 weeks since prior radiotherapy and recovered

        Surgery:

          -  Not specified

        Other:

          -  At least 28 days since any prior systemic therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lee J. Helman, MD</last_name>
    <role>Study Chair</role>
    <affiliation>National Cancer Institute (NCI)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jonsson Comprehensive Cancer Center, UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095-1781</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington Hospital Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lutheran General Cancer Care Center</name>
      <address>
        <city>Park Ridge</city>
        <state>Illinois</state>
        <zip>60068</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892-1182</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan Comprehensive Cancer Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109-0912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Cancer Center</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021-6007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herbert Irving Comprehensive Cancer Center at Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas - MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-4009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Chugh R, Wathen JK, Maki RG, Benjamin RS, Patel SR, Meyers PA, Priebat DA, Reinke DK, Thomas DG, Keohan ML, Samuels BL, Baker LH. Phase II multicenter trial of imatinib in 10 histologic subtypes of sarcoma using a bayesian hierarchical statistical model. J Clin Oncol. 2009 Jul 1;27(19):3148-53. doi: 10.1200/JCO.2008.20.5054. Epub 2009 May 18. Erratum in: J Clin Oncol. 2009 Sep 20;27(27):4630. Myers, Paul A [corrected to Meyers, Paul A].</citation>
    <PMID>19451433</PMID>
  </results_reference>
  <verification_date>October 2003</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 8, 2002</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>June 17, 2013</last_update_submitted>
  <last_update_submitted_qc>June 17, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 19, 2013</last_update_posted>
  <keyword>metastatic osteosarcoma</keyword>
  <keyword>recurrent childhood rhabdomyosarcoma</keyword>
  <keyword>recurrent osteosarcoma</keyword>
  <keyword>embryonal childhood rhabdomyosarcoma</keyword>
  <keyword>alveolar childhood rhabdomyosarcoma</keyword>
  <keyword>pleomorphic childhood rhabdomyosarcoma</keyword>
  <keyword>metastatic childhood soft tissue sarcoma</keyword>
  <keyword>recurrent childhood soft tissue sarcoma</keyword>
  <keyword>childhood fibrosarcoma</keyword>
  <keyword>childhood synovial sarcoma</keyword>
  <keyword>childhood liposarcoma</keyword>
  <keyword>childhood alveolar soft-part sarcoma</keyword>
  <keyword>childhood neurofibrosarcoma</keyword>
  <keyword>childhood angiosarcoma</keyword>
  <keyword>childhood malignant fibrous histiocytoma of bone</keyword>
  <keyword>previously treated childhood rhabdomyosarcoma</keyword>
  <keyword>metastatic Ewing sarcoma/peripheral primitive neuroectodermal tumor</keyword>
  <keyword>recurrent Ewing sarcoma/peripheral primitive neuroectodermal tumor</keyword>
  <keyword>fibrosarcomatous osteosarcoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
    <mesh_term>Osteosarcoma</mesh_term>
    <mesh_term>Histiocytoma</mesh_term>
    <mesh_term>Histiocytoma, Benign Fibrous</mesh_term>
    <mesh_term>Histiocytoma, Malignant Fibrous</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Imatinib Mesylate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

